Compare USLM & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | RCUS |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 1994 | 2018 |
| Metric | USLM | RCUS |
|---|---|---|
| Price | $109.84 | $25.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $138.00 | $31.90 |
| AVG Volume (30 Days) | 119.9K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | $144,435,000.00 | ★ $247,000,000.00 |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $13.76 | $45.62 |
| P/E Ratio | $103.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $94.41 | $7.92 |
| 52 Week High | $141.44 | $28.72 |
| Indicator | USLM | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 56.18 |
| Support Level | $107.82 | $19.78 |
| Resistance Level | $129.37 | $28.72 |
| Average True Range (ATR) | 6.32 | 1.76 |
| MACD | -2.53 | -0.04 |
| Stochastic Oscillator | 19.27 | 61.39 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.